• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 8-A12B/A filed by Jade Biosciences Inc.

    8/13/25 4:26:32 PM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JBIO alert in real time by email
    8-A12B/A 1 d89363d8a12ba.htm 8-A12B/A 8-A12B/A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-A/A

    Amendment No. 1

     

     

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

    PURSUANT TO SECTION 12(b) OR (g) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

     

    Jade Biosciences, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Nevada   83-1377888
    (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

     

    221 Crescent St., Building 23
    Suite 105
    Waltham, MA
      02453
    (Address or principal executive offices)   (Zip Code)

    Securities to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class
    to be so registered

     

    Name of each exchange on which
    each class is to be registered

    Common Stock, $0.0001 par value per share   The Nasdaq Capital Market

     

     

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General instruction A.(c), check the following box. ☑

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ☐

    Securities Act registration statement file number to which this form relates:

    333-283562

    Securities to be registered pursuant to Section 12(g) of the Act:

    None

     

     
     


    EXPLANATORY NOTE

    On April 16, 2025, the shareholders of Aerovate Therapeutics, Inc., a Delaware corporation (“Aerovate”), approved (i) a merger (the “Merger”) with Jade Biosciences, Inc., a Delaware corporation (the “Private Jade”), and (ii) the redomestication of Aerovate from the State of Delaware to the State of Nevada by conversion (the “Redomestication”). On April 28, 2025, the Merger was consummated, whereby Private Jade became a wholly-owned subsidiary of Aerovate and subsequently merged with and into Aerovate, with Aerovate as the surviving corporation. Also on April 28, 2025, Aerovate changed its name to “Jade Biosciences, Inc.” (“Jade Delaware”) and completed the Redomestication from Delaware to Nevada (hereinafter, “Jade Nevada”). As a result of and upon the effective time of the Redomestication, among other things, each share of common stock, par value $0.0001 per share, of Jade Delaware (the “Jade Delaware Common Stock”) issued and outstanding immediately prior to the Redomestication converted, on a one-for-one basis, into a duly authorized, validly issued, fully paid and nonassessable share of common stock, par value $0.0001 per share, of Jade Nevada (the “Jade Nevada Common Stock”).

    This Amendment No. 1 to the Aerovate Registration Statement on Form 8-A filed on June 25, 2021 is being filed to (i) expressly assume the registration of the Jade Nevada Common Stock, pursuant to Rule 12g-3 under the Securities Exchange Act of 1934, as amended; and (ii) to amend and restate the description of the Jade Delaware Common Stock to reflect the fact that such shares are now shares of Jade Nevada Common Stock.

    Item 1. Description of Registrant’s Securities to be Registered.

    DESCRIPTION OF JADE CAPITAL STOCK

    The following description of the Company’s capital stock and provisions of the Company’s articles of incorporation and bylaws are summaries and are qualified by reference to such articles of incorporation and bylaws and applicable provisions of Nevada corporate law. The Company has filed copies of these documents as exhibits to this Registration Statement.

    General

    Jade Nevada’s authorized capital stock consists of 300,000,000 shares of common stock, par value $0.0001 per share (“Common Stock”), and 10,000,000 shares of preferred stock, par value $0.0001 per share (“Preferred Stock”), 12,622 of which are designated as Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”).

    Common Stock

    The Company’s articles of incorporation authorize the issuance of up to 300,000,000 shares of Common Stock. All outstanding shares of Common Stock are validly issued, fully paid and nonassessable.

    Distribution Rights

    Subject to preferences that may apply to any shares of Preferred Stock outstanding at the time, the holders of Common Stock are entitled to receive dividends and other distributions out of assets or funds legally available if the Company’s board of directors or an authorized committee thereof (the “Board”), in its discretion, determines to issue such dividends or make such other distributions and then only at the times and in the amounts that the Board may determine.

    Voting Rights

    Holders of Common Stock are entitled to one vote for each such share held of record on the applicable record date on each matter properly submitted to and voted on at a meeting of stockholders, except that holders of Common Stock shall not be entitled to vote on any amendment to the articles of incorporation that alters or changes the powers, preferences, rights or other terms of any outstanding class or series of Preferred Stock if the holders of the affected class(es) or series of such Preferred Stock are entitled to vote, either separately or together with the holders of one or more other such class(es) or series, on such amendment pursuant to the articles of incorporation (including any certificate of designation relating to such class(es) or series of Preferred Stock) or pursuant to the Nevada Revised Statutes (the “NRS”).


    Classified Board

    The number of directors shall be fixed by the Board. Other than any directors elected by the separate vote of the holders of any class or series of Preferred Stock, the members of the Board will be divided into three classes, designated as Class I, Class II and Class III, respectively, with directors assigned to each class by the Board. At each annual meeting of stockholders, directors will be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting (but at least one-fourth of the total number of the directors must be elected annually). Notwithstanding the foregoing, directors elected to each class will hold office until their successors are duly elected and qualified or until their earlier resignation, death or removal. Directors will be elected by a plurality of the votes properly cast.

    No Preemptive or Similar Rights

    The Common Stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions.

    Right to Received Liquidation Distributions

    Upon the Company’s liquidation, dissolution or winding-up, the assets legally available for distribution to stockholders would be distributable ratably to and among the holders of Common Stock and any participating Preferred Stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of Preferred Stock.

    Preferred Stock

    Under the terms of the Company’s articles of incorporation, the Board is authorized, subject to limitations prescribed by Nevada law, to issue up to 10,000,000 shares of Preferred Stock in one or more series, to establish and designate from time to time shares of Preferred Stock in one or more classes or series, to fix the number of shares to be included in each class or series and to fix the voting powers (if any), designations, powers, preferences, limitations, restrictions and relative rights of the shares of each series, in each case without further vote or action by the Company’s stockholders. Subject to any certificates of designation on file with the Nevada Secretary of State, the Board can also increase or decrease the number of shares of any series of Preferred Stock, but not below the number of shares of that series then outstanding, without any further vote or action by the Company’s stockholders. The Board may authorize the issuance of Preferred Stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of Common Stock. The issuance of Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of the Company and might adversely affect the market price of the Common Stock and the voting and other rights of the holders of Common Stock.

    Series A Non-Voting Convertible Preferred Stock

    The Board has designated 12,622 shares of Preferred Stock as Series A Preferred Stock through a certificate of designation filed as Exhibit 3.3 to this Registration Statement (the “Certificate of Designation”). Holders of the Series A Preferred Stock are entitled to receive dividends and other distributions on shares of Series A Preferred Stock equal to, on an as-if-converted-to-Common Stock basis, and in the same form as dividends and other distributions (other than dividends on shares of Common Stock payable in the form of Common Stock) actually paid on shares of Common Stock when, as and if such distributions are paid on shares of Common Stock. Except as otherwise required by the Certificate of Designation or law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without


    the affirmative vote of the holders of a majority of the then-outstanding shares of the Series A Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company’s articles of incorporation or bylaws, or file any certificate of designation (or any amendment thereto) relating to any series of Preferred Stock, in each case if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Company’s articles of incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii) issue further shares of the Series A Preferred Stock beyond those contemplated for issuance in the Merger Agreement (as defined in the Certificate of Designation) or increase or decrease (other than by conversion) the number of authorized shares of the Series A Preferred Stock, (iii) at any time while at least 3,786 shares of Series A Preferred Stock remains issued and outstanding, consummate either: (A) any Fundamental Transaction (as defined in the Certificate of Designation) or (B) any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority on an as-converted-to-common stock basis of the capital stock of the Company, immediately after such transaction or (iv) enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated herein to consummate such transaction.

    The Series A Preferred Stock ranks on parity with the Common Stock as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily. Each share of Series A Preferred Stock is convertible, at any time and from time to time, at the option of the holder of the Series A Preferred Stock, into 1,000 shares of Common Stock, subject to certain limitations (and subject further to adjustment as set forth in the Certificate of Designation), including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 19.99%) of the total number of shares of Common Stock outstanding or deemed to be outstanding immediately after giving effect to such conversion.

    Anti-Takeover Provisions

    Certain provisions of Nevada law, the Company’s articles of incorporation and the Company’s bylaws could have the effect of delaying, deferring, discouraging or preventing another person from acquiring control of the Company. These anti-takeover provisions, which are summarized below, may have the effect of discouraging proxy contests and takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of the Company to negotiate first with the Board. The Company believes that the benefits of increased protection of its potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire the Company because negotiation of these proposals could result in an improvement of their terms.

    Combinations with Interested Stockholder Statutes

    Nevada’s “combinations with interested stockholders” statutes (NRS 78.411 to 78.444) provide that specified types of business “combinations” between certain Nevada corporations and any person deemed to be an “interested stockholder” of the corporation are prohibited for a period of two years following the date on which the person first became an interested stockholder unless:

     

      •  

    prior to the date the person first became an interested stockholder, the Board approved either the combination or the transaction which resulted in the stockholder becoming an interested stockholder; or

     

      •  

    at or after the time on which such stockholder becomes an interested stockholder, the combination is approved by the Board and 60% of the corporation’s voting power not beneficially owned by the interested stockholder, its affiliates and associates.

    Furthermore, in the absence of prior approval, even after the two-year period described above, a combination remains prohibited for another two years unless (i) it is approved by the Board, the disinterested stockholders or a majority of the outstanding voting power not beneficially owned by the interested stockholder and its affiliates and associates or (ii) the terms of the combination satisfy certain fair value requirements. However, these statutes do not apply to any combination of a corporation and an interested stockholder after the expiration of four years after the person first became an interested stockholder.


    An “interested stockholder” is any person who is (1) the beneficial owner, directly or indirectly, of 10% or more of the voting power of the outstanding voting shares of the corporation, or (2) an affiliate or associate of the corporation and at any time within the two previous years was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then-outstanding shares of the corporation. The definition of the term “combination” is sufficiently broad to cover most significant transactions between a corporation and an “interested stockholder”, including mergers and consolidations, sales, leases, exchanges, pledges, transfers or other dispositions of assets with a certain market value, earning power or net income, and share issuances with a certain market value.

    These statutes generally apply to Nevada corporations with 200 or more stockholders of record. At this time, the Company does not have 200 or more stockholders of record. A Nevada corporation may elect in its articles of incorporation not to be governed by these particular laws, but if such election is not made in the corporation’s original articles of incorporation, the amendment (1) must be approved by the affirmative vote of the holders of stock representing a majority of the outstanding voting power of the corporation not beneficially owned by interested stockholders or their affiliates and associates, and (2) is not effective until 18 months after the vote approving the amendment and does not apply to any combination with a person who first became an interested stockholder on or before the effective date of the amendment. The Company does not have an opt-out election in its original articles of incorporation.

    Acquisition of Controlling Interest Statutes

    Nevada’s “acquisition of controlling interest” statutes (NRS 78.378 to 78.3793) prohibit an acquirer, under certain circumstances, from voting its shares of a corporation’s stock after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the corporation’s disinterested stockholders. The statute specifies three thresholds: one-fifth or more but less than one-third, one-third but less than a majority, and a majority or more, of the outstanding voting power. Generally, once an acquirer crosses one of the above thresholds, those shares in an offer or acquisition and acquired within 90 days thereof become “control shares” and such control shares are deprived of the right to vote until disinterested stockholders restore the right. These provisions also provide that if control shares are accorded full voting rights and the acquiring person has acquired a majority or more of all voting power, all other stockholders who do not vote in favor of authorizing voting rights to the control shares are entitled to demand payment for the fair value of their shares in accordance with Nevada’s dissenter’s rights statutes.

    A corporation may elect to not be governed by the acquisition of controlling interest statutes by making an election in its articles of incorporation or bylaws, provided that the opt-out election must be in place on the tenth day following the date an acquiring person has acquired a controlling interest, that is, crossing any of the three thresholds described above. The Company has opted out of the acquisition of controlling interest statutes in its bylaws.

    Articles of Incorporation and Bylaw Provisions

    The Company’s articles of incorporation and bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of the Company, including the following:

     

      •  

    Board of Directors Vacancies: The Company’s articles of incorporation and bylaws require that the Board, and not stockholders, fill any directorships that become vacant or are created by an increase in the authorized number of directors by the affirmative vote of a majority of the remaining directors or by the sole remaining director. In addition, pursuant to the Company’s bylaws, the number of directors constituting the Board is permitted to be set only by a resolution adopted by a majority vote of the Board. These provisions prevent a stockholder from increasing the size of the Board and then gaining control of the Board by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of the Board but promotes continuity of management.


      •  

    Classified Board: The Company’s articles of incorporation provide that the Board is classified into three classes of directors, each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of the Company as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors.

     

      •  

    Stockholder Action; Special Meetings of Stockholders: The Company’s articles of incorporation and bylaws provide that stockholders may not take action by written consent, but may only take action at annual or special meetings of stockholders. As a result, a holder controlling a majority of the Company’s capital stock would not be able to amend the Company’s bylaws or remove directors without holding a meeting of stockholders called in accordance with the Company’s bylaws. Further, the bylaws provide that special meetings of stockholders may be called only by the Board, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of stockholders to force consideration of a proposal or for stockholders controlling a majority of the Company’s capital stock to take any action, including the removal of directors.

     

      •  

    Advance Notice Requirements for Stockholder Proposals and Director Nominations: The Company’s bylaws provide advance notice procedures for stockholders seeking to bring business before the annual meeting of stockholders or to nominate candidates for election as directors at the annual meeting of stockholders. The Company’s bylaws also specify certain requirements regarding the form and content of a stockholder’s notice. These provisions might preclude stockholders from bringing matters before the annual meeting of stockholders or from making nominations for directors at the annual meeting of stockholders if the proper procedures are not followed. The Company expects that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of the Company.

     

      •  

    No Cumulative Voting: The NRS provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation’s articles of incorporation provides otherwise. The Company’s articles of incorporation do not provide for cumulative voting.

     

      •  

    Directors Removed Only for Cause: The Company’s articles of incorporation provide that stockholders may remove directors only for cause, and only by the affirmative vote of the holders of not less than two-thirds (2/3) of the voting power of the outstanding stock entitled to vote in the election of directors.

     

      •  

    Amendment of Charter Provisions: The affirmative vote of a majority of the voting power of the outstanding shares of capital stock entitled to vote, and the affirmative vote of a majority of the voting power of the outstanding shares of each class of capital stock entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose, is required to amend or repeal provisions of the Company’s articles of incorporation; provided, however, that the affirmative vote of not less than two-thirds (2/3) of the voting power of the outstanding shares of capital stock entitled to vote on such amendment or repeal, and the affirmative vote of not less than two-thirds (2/3) of the voting power of the outstanding shares of each class entitled to vote thereon as a class, shall be required to amend or repeal any provision of Article V (Stockholder Action), Article VI (Directors), Article VII (Limitation of Liability), Article VIII (Amendment of Bylaws) or Article IX (Amendment of Articles of Incorporation) of the Company’s articles of incorporation.

     

      •  

    Issuance of Preferred Stock: The Board has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of Preferred Stock with rights and preferences, including voting rights, designated from time to time by the Board. The existence of authorized but unissued shares of Preferred Stock enables the Board to render more difficult or to discourage an attempt to obtain control of the Company by merger, tender offer, proxy contest or other means.

     

      •  

    Choice of Forum: The Company’s bylaws provide that, unless the Company consents in writing to the selection of an alternative forum, the Eighth Judicial District Court of Clark County, Nevada (or, if such state court lacks jurisdiction, then any other state or federal district court located in the State of Nevada), shall be the sole and exclusive forum for any action, suit, proceeding or claim (i) brought in the name or


     

    right or on behalf of the Company, (ii) for or based upon a breach of any fiduciary duty owed by any director, officer, employee or agent of the Company in such capacity, (iii) arising pursuant to, or to interpret, apply, enforce or determine the validity of, any provision of NRS Title 7 (including without limitation NRS Chapters 78 and 92A), the Company’s articles of incorporation or bylaws, or as to which the NRS confers jurisdiction on the courts of the State of Nevada, or (iv) asserting a claim governed by the internal affairs doctrine. In addition, the Company’s bylaws also provide that the federal district courts of the United States are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions do not apply to claims brought to enforce a duty or liability created by the Exchange Act.

    Transfer Agent and Registrar

    The transfer agent and registrar for the Common Stock is Computershare Trust Company, N.A. The transfer agent’s address is 150 Royall Street, Suite 101, Canton, MA 02021, and its telephone number is (800) 344-5128.

    Listing

    The Common Stock is listed on The Nasdaq Capital Market under the symbol “JBIO.”

    Item 2. Exhibits.

     

    Exhibit No.    Description of Document
    2.1    Plan of Conversion, dated April 30, 2025 (incorporated by reference to Exhibit 2.2 to the Registrant’s Current Report on Form 8-K (File No. 001-40544) filed with the SEC on May 1, 2025).
    3.1    Articles of Incorporation of Jade Biosciences, Inc., effective April  28, 2025 (incorporated by reference to Exhibit 3.4 to the Registrant’s Current Report on Form 8-K (File No.  001-40544) filed with the SEC on May 1, 2025).
    3.2    Bylaws of Jade Biosciences, Inc., effective April  28, 2025 (incorporated by reference to Exhibit 3.5 to the Registrant’s Current Report on Form 8-K (File No.  001-40544) filed with the SEC on May 1, 2025).
    3.3    Certificate of Designation of Series A Non-Voting Convertible Preferred Stock, effective April 28, 2025 (incorporated by reference to Exhibit 3.7 to the Registrant’s Current Report on Form 8-K (File No. 001-40544) filed with the SEC on May 1, 2025).


    SIGNATURE

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed its behalf by the undersigned, thereunto duly authorized.

    Dated: August 13, 2025

     

    JADE BIOSCIENCES, INC.
    By:   /s/ Tom Frohlich
      Tom Frohlich
      Chief Executive Officer
    Get the next $JBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JBIO

    DatePrice TargetRatingAnalyst
    10/9/2025$28.00Buy
    BTIG Research
    7/14/2025$16.00Buy
    Jefferies
    6/16/2025$14.00Neutral → Buy
    Guggenheim
    5/7/2025$17.00Outperform
    Wedbush
    5/5/2025$19.00Buy
    Stifel
    5/2/2025$10.00Buy
    TD Cowen
    More analyst ratings

    $JBIO
    SEC Filings

    View All

    Jade Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure

    8-K - Jade Biosciences, Inc. (0001798749) (Filer)

    12/15/25 7:11:11 AM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-1 filed by Jade Biosciences Inc.

    S-1 - Jade Biosciences, Inc. (0001798749) (Filer)

    11/14/25 4:09:41 PM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Jade Biosciences Inc.

    10-Q - Jade Biosciences, Inc. (0001798749) (Filer)

    11/14/25 7:13:30 AM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jade Biosciences Announces $45 Million Private Placement

    SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement with BB Biotech for a private placement financing that is expected to result in gross proceeds of approximately $45 million to the Company, before offering expenses. Pursuant to the terms of the securities purchase agreement, Jade is selling an aggregate of 3,214,286 shares of its common stock ("Common Stock") at a purchase price of $14.00 per share. The private pla

    12/15/25 7:00:00 AM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its potential as a best-in-class selective anti-APRIL monoclonal antibody for IgA nephropathy Initiated Phase 1 healthy volunteer study of JADE101; interim, biomarker-rich data expected in the first half of 2026 are anticipated to define dose and dose interval selection for patient trials Unveiled JADE201, a potentially best-in-class, half-life extended, afucosylated anti-BAFF receptor monoclonal antibody; first-in-human trial in rheumatoid arthritis expected to begin in the first half of 2026 with pot

    11/13/25 4:05:00 PM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

    SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today presented two posters for JADE101, its investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2025. JADE101 is designed to selectively inhibit APRIL, a key driver of pathogenic IgA production in IgAN, a progressive autoimmune disease that frequently leads to end-stage kidney disease over a pati

    11/8/25 11:00:00 AM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc was granted 1,333,126 shares (SEC Form 4)

    4 - Jade Biosciences, Inc. (0001798749) (Issuer)

    10/8/25 4:15:17 PM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Dahms Bradford D.

    4 - Jade Biosciences, Inc. (0001798749) (Issuer)

    7/14/25 7:12:40 PM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Dahms Bradford D.

    3 - Jade Biosciences, Inc. (0001798749) (Issuer)

    7/14/25 7:10:59 PM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Jade Biosciences with a new price target

    BTIG Research initiated coverage of Jade Biosciences with a rating of Buy and set a new price target of $28.00

    10/9/25 8:27:03 AM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Jade Biosciences with a new price target

    Jefferies initiated coverage of Jade Biosciences with a rating of Buy and set a new price target of $16.00

    7/14/25 8:52:19 AM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jade Biosciences upgraded by Guggenheim with a new price target

    Guggenheim upgraded Jade Biosciences from Neutral to Buy and set a new price target of $14.00

    6/16/25 7:42:14 AM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Frohlich Tom bought $44,400 worth of shares (6,000 units at $7.40) (SEC Form 4)

    4 - Jade Biosciences, Inc. (0001798749) (Issuer)

    5/19/25 4:54:17 PM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JBIO
    Financials

    Live finance-specific insights

    View All

    Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

    JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less frequent subcutaneous dosing JADE201's high affinity binding and extended half-life enabled dose-dependent BAFF receptor occupancy and sustained B cell depletion in non-human primatesFirst-in-human trial in rheumatoid arthritis expected to begin in the first half of 2026; potential for broad opportunity across multiple autoimmune diseases validated by BAFF-R biologyCompany to host conference call and webcast today at 8:00 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia,

    10/7/25 7:05:00 AM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

    Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a differentiated pharmacokinetic and pharmacodynamic profile with deep and sustained IgA reductions and the potential to support convenient subcutaneous dosing every eight weeks or longer First-in-human trial expected to begin second half 2025; biomarker-rich interim data in healthy volunteers expected first-half 2026 to inform patient dose and schedule Company to host conference call and webcast today, June 9, 2025, at 8:00 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia, June

    6/9/25 7:00:00 AM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

    SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025. The presentation, titled "Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN," will be delivered

    6/2/25 7:00:00 AM ET
    $JBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care